Molecular Profile Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Profile Name ERBB2 exon 20 ins
Gene Variant Detail

ERBB2 exon 20 ins (unknown)

Relevant Treatment Approaches HER inhibitor (Pan) HER2 Inhibitor

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Clinical Trial Phase Therapies Title Recruitment Status
NCT04335292 Phase II Cisplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium Osimertinib Osimertinib Then Chemotherapy in EGFR-mutated Lung Cancer With Osimertinib Third-line Rechallenge (OCELOT) Not yet recruiting
NCT04172597 Phase II Poziotinib A Study of Poziotinib in Patients With EGFR or HER2 Activating Mutations in Advanced Malignancies Recruiting
NCT03066206 Phase II Poziotinib Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC Recruiting
NCT02716116 Phase Ib/II AP32788 A Trial of TAK-788 (AP32788) in Non-small Cell Lung Cancer (NSCLC) Active, not recruiting
NCT03318939 Phase II Poziotinib Phase 2 Study of Poziotinib in Patients With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation Recruiting
NCT04209465 Phase I BDTX-189 A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors. Recruiting